CA-MONTE-CARLO
20.5.2021 13:02:14 CEST | Business Wire | Press release
Monte Carlo , the data reliability company, today announced Berlin-based microlearning app Blinkist has selected Monte Carlo to achieve more reliable data through data observability.
As a high-growth company with over 16 million users worldwide, Blinkist leverages paid performance marketing to fuel customer acquisition — and those channels rely on accurate behavioral data to optimize campaign spend. Like many companies today, Blinkist’s data engineering teams have been challenged by broken pipelines, missing or inaccurate data, and a subsequent lack of trust in data across their organization.
Monte Carlo is an end-to-end Data Observability Platform that enables data teams at companies like Blinkist to seamlessly monitor the health of their data assets by applying the proven principles of application observability to data. Simultaneously, Monte Carlo provides CDOs and other data stakeholders with a holistic view of their company’s data health and reliability across critical business use cases.
“For Blinkist, having trustworthy and reliable data is foundational to the success of our business. When the pandemic hit, real-time data became even more crucial to understand the reality of our audience’s daily lives,” stated Gopi Krishnamurthy, Director of Engineering at Blinkist. “Any inaccuracies were both timely and costly; our team was spending 50% of their time on fixing these. Monte Carlo enabled us to adopt data reliability engineering principles and increased transparency about data health across the company.”
After onboarding Monte Carlo, the platform’s automated monitoring and intelligent alerting has already allowed Blinkist data engineers to reclaim up to 120 hours per week and enabled them to focus on innovation and product, rather than firefighting data issues. The Monte Carlo platform also helps their team build organizational trust in data by providing visibility into issues, and delivers the confidence Blinkist engineers need to implement and maintain data-specific Service Level Agreements (SLAs).
With more reliable and accurate data in place, Blinkist marketers can now make swift decisions to improve targeting and performance, leading to higher overall revenue for the company.
“We are thrilled that Blinkist has chosen Monte Carlo as their data reliability partner,” stated Barr Moses, CEO and co-founder of Monte Carlo. “In today’s environment, data is a company’s most critical asset. Our team is proud to help Blinkist unlock the potential of their data.”
About Monte Carlo
As businesses increasingly rely on data to drive better decision making, it’s mission-critical that this data is accurate and reliable. Billed by Forbes as the New Relic for data teams and backed by Accel and GGV, Monte Carlo solves the costly problem of broken data through their fully automated, SOC-2 certified data observability platform.
About Blinkist
Blinkist is a Berlin-based microlearning app that has grown to over 16 million users worldwide since its launch in 2012. A pioneer in new audio learning formats, their library of over 4,000 titles-turned-Blinks includes topics like society and culture, wellness, parenting, leadership, and more. Blinkist products are curated by editorial experts in collaboration with high-profile, expert creators across a wide variety of fields. Their formats include Blinks, Audiobooks, and now, Shortcasts, accessible across all iOS and Android mobile devices.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005096/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
